Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced results from five analyses of 12-month data from ETNA-VTE (Edoxaban Treatment...
Registry provides new insights into AF treatment decisions, including patients' quality of life and treatment satisfaction[1],[2] (Photo:...
La Journée Mondiale de l'Hypertension a lieu chaque année le 17 mai. Le thème choisi pour 2014 est "Connaître Votre Pression Artérielle". La Journée...
Daiichi Sankyo e "Little Hearts" insieme per gli orfani dell'Est Europa Il 17 maggio ricorre la decima edizione della Giornata Mondiale contro...
Daiichi Sankyo pone en marcha la iniciativa "Haz que tu corazón se sienta bien" El 17 de mayo se celebra el Día Mundial de la Hipertensión, cuyo lema ...
For European Media Only, Not for UK Media Atrial fibrillation (AF) is the most common heart rhythm disorder[1] resulting in a five-fold increased...
El estudio SEVITENSION demuestra la superioridad de Sevikar® (olmesartán y amlodipino) frente a la combinación de perindopril y amlodipino en la...
De nouvelles données de l'étude SEVITENSION montrent la supériorité de l'association à doses fixes Sevikar® (olmésartan/amlodipine) comparé à...
Nel corso del 23° Congresso della Società Europea di Ipertensione sono stati presentati gli ultimi dati dello studio SEVITENSION, che mostrano...
The registry plans to gather data from more than 4,000 patients with VTE across seven European countries, providing insights into the clinical...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.